ATE441631T1 - Phenylpiperidinderivate als serotonin- wiederaufnahmehemmer - Google Patents

Phenylpiperidinderivate als serotonin- wiederaufnahmehemmer

Info

Publication number
ATE441631T1
ATE441631T1 AT06016609T AT06016609T ATE441631T1 AT E441631 T1 ATE441631 T1 AT E441631T1 AT 06016609 T AT06016609 T AT 06016609T AT 06016609 T AT06016609 T AT 06016609T AT E441631 T1 ATE441631 T1 AT E441631T1
Authority
AT
Austria
Prior art keywords
reuppost
serotonin
inhibitors
phenylpiperidine derivatives
phenylpiperidine
Prior art date
Application number
AT06016609T
Other languages
English (en)
Inventor
Thomas Ruhland
Garrick Paul Smith
Benny Bang-Andersen
Ask Puschl
Ejner Knud Moltzen
Kim Andersen
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8160750&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE441631(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Application granted granted Critical
Publication of ATE441631T1 publication Critical patent/ATE441631T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AT06016609T 2001-10-04 2002-10-02 Phenylpiperidinderivate als serotonin- wiederaufnahmehemmer ATE441631T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200101466 2001-10-04

Publications (1)

Publication Number Publication Date
ATE441631T1 true ATE441631T1 (de) 2009-09-15

Family

ID=8160750

Family Applications (2)

Application Number Title Priority Date Filing Date
AT06016609T ATE441631T1 (de) 2001-10-04 2002-10-02 Phenylpiperidinderivate als serotonin- wiederaufnahmehemmer
AT02800051T ATE386730T1 (de) 2001-10-04 2002-10-02 Phenylpiperazinderivate als serotonin wiederaufnahmehemmer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT02800051T ATE386730T1 (de) 2001-10-04 2002-10-02 Phenylpiperazinderivate als serotonin wiederaufnahmehemmer

Country Status (39)

Country Link
US (10) US7144884B2 (de)
EP (2) EP1436271B3 (de)
JP (3) JP3896116B2 (de)
KR (3) KR100783346B1 (de)
CN (1) CN1319958C (de)
AR (2) AR036659A1 (de)
AT (2) ATE441631T1 (de)
AU (2) AU2002333220C1 (de)
BE (1) BE2014C036I2 (de)
BR (3) BR122012023120B8 (de)
CA (1) CA2462110C (de)
CO (1) CO5580746A2 (de)
CY (3) CY1107924T1 (de)
DE (2) DE60225162T3 (de)
DK (2) DK1436271T6 (de)
EA (2) EA011096B1 (de)
EG (1) EG25095A (de)
ES (2) ES2328725T3 (de)
FR (1) FR14C0033I2 (de)
HK (1) HK1072600A1 (de)
HR (1) HRP20040220A2 (de)
HU (3) HU228956B1 (de)
IL (1) IL160655A0 (de)
IS (2) IS2578B (de)
LT (1) LTC1436271I2 (de)
LU (1) LU92397I2 (de)
ME (1) ME00039B (de)
MX (1) MXPA04002959A (de)
MY (1) MY140950A (de)
NL (1) NL300652I1 (de)
NO (3) NO326443B1 (de)
NZ (1) NZ531556A (de)
PL (2) PL209253B1 (de)
PT (2) PT1749818E (de)
RS (2) RS52326B (de)
SI (1) SI1436271T1 (de)
UA (2) UA81749C2 (de)
WO (1) WO2003029232A1 (de)
ZA (1) ZA200401583B (de)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
GB0305575D0 (en) * 2003-03-11 2003-04-16 Glaxo Group Ltd Novel compounds
UA81300C2 (en) * 2003-04-04 2007-12-25 Lundbeck & Co As H Derivates of 4-(2-fenilsulfanilfenil)-1,2,3,6-tetrahydropiridin as retarding agents of serotonin recapture
UA81472C2 (en) * 2003-04-04 2008-01-10 Lundbeck & Co As H 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
US7732463B2 (en) * 2003-04-04 2010-06-08 H. Lundbeck A/S 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
EP1635828B1 (de) * 2003-04-04 2008-04-23 H. Lundbeck A/S 4-(2-phenyloxyphenyl)-piperidin- oder -1,2,3,6-tetrahydropyridin-derivate als serotonin-wiederaufnahme-hemmer
ZA200505031B (en) * 2003-04-04 2006-09-27 Lundbeck & Co As H 4-(2-Phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahy-dropyridine derivatives as serotonin reuptake inhibitors
AU2004303461B2 (en) 2003-12-23 2011-04-28 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-benzyl amine derivatives as SSRI
AR052308A1 (es) * 2004-07-16 2007-03-14 Lundbeck & Co As H Derivados de 2-(1h-indolilsulfanil)-arilamina y una composicion farmaceutica que contiene al compuesto
ATE435216T1 (de) 2005-02-10 2009-07-15 Neurosearch As Alkylsubstituierte homopiperazinderivate und deren verwendung als monoamin neurotransmitter wiederaufnahmeinhibitoren
US7629473B2 (en) 2005-06-17 2009-12-08 H. Lundbeck A/S 2-(1H-indolylsulfanyl)-aryl amine derivatives
AR054393A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de benzo(b)furano y benzo(b)tiofeno, composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la reabsorcion de neurotransmisores de amina biogenicos.
AR054394A1 (es) * 2005-06-17 2007-06-20 Lundbeck & Co As H Derivados de 2- (1h-indolilsulfanil)-aril amina
JP2007106746A (ja) * 2005-09-13 2007-04-26 Tosoh Corp 新規アリールホモピペラジン類、またはその塩と製造方法
UA95801C2 (ru) * 2006-06-16 2011-09-12 Х. Луннбек А/С Кристаллические формы 4-[2-(4-метилфенилсульфанил)-фенил]пиперидина с комбинированным ингибированием обратного захвата серотонина и норэпинефрина для лечения невропатической боли
MY150698A (en) * 2006-06-16 2014-02-28 Lundbeck & Co As H Crystalline forms of 4- [2- (-methylphenylsulfanyl) -phenyl] piperidine with combined serotonin and norepinephrine reuptake inhibition for the treatment of neuropathic pain
JP7179035B2 (ja) * 2006-06-16 2022-11-28 ハー・ルンドベック・アクチエゼルスカベット 認識機能障害（ｃｏｇｎｉｔｉｖｅ ｉｍｐａｉｒｍｅｎｔ）を治療するための、組み合わされたセロトニン再取り込み、５－ＨＴ３および５－ＨＴ１Ａ活性を有する化合物としての１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
RS52205B2 (sr) * 2006-06-16 2021-05-31 H Lundbeck A/S 1-[2-(2,4-dimetilfenilsulfanil)-fenil]piperazin kao jedinjenje sa kombinovanom aktivnošću ponovnog uzimanja serotonina, 5-ht3 i 5-ht1a, za tretman kognitivnih oštećenja
PL2044020T3 (pl) * 2006-06-16 2011-09-30 H Lundbeck As Krystaliczne postaci 4-[2-(4-metylofenylosulfanylo)-fenylo]piperydyny z równoczesnym hamowaniem wychwytu zwrotnego serotoniny i norepinefryny do leczenia bólu neuropatycznego
TWI405588B (zh) * 2007-03-20 2013-08-21 Lundbeck & Co As H ４-〔２-（４-甲苯基硫基）-苯基〕哌啶之鹽類的液體調配物
TWI432194B (zh) * 2007-03-20 2014-04-01 Lundbeck & Co As H ４-〔２-（４-甲基苯硫基）苯基〕哌啶之新穎治療用途
TW200848411A (en) * 2007-03-20 2008-12-16 Lundbeck & Co As H Novel therapeutic uses of 1-[2-(2, 4-dimethylphenylsulfanyl)phenyl]-piperazine
JP5764327B2 (ja) * 2007-06-15 2015-08-19 ハー・ルンドベック・アクチエゼルスカベット 過敏性腸症候群（ｉｂｓ）を処置するための４−［２−（４−メチルフェニルスルファニル）フェニル］ピペリジン
AU2014200364B2 (en) * 2007-11-13 2015-09-17 H. Lundbeck A/S Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1A activity
TW200932233A (en) * 2007-11-13 2009-08-01 Lundbeck & Co As H Therapeutic uses of compounds having combined SERT, 5-HT3 and 5-HT1a activity
TW200932225A (en) * 2007-12-14 2009-08-01 Lundbeck & Co As H 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine
TW200938194A (en) * 2007-12-14 2009-09-16 Lundbeck & Co As H Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter
WO2009081259A1 (en) * 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
UA98698C2 (en) * 2008-03-03 2012-06-11 Х. Луннбек А/С Phenylsulfanylphenyl-piperidines and process for the preparation thereof
CA2742114C (en) 2008-11-14 2016-09-13 Theravance, Inc. Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
TW201033181A (en) 2009-02-17 2010-09-16 Lundbeck & Co As H Purification of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine
GEP20135938B (en) * 2009-04-24 2013-10-10 H Lundbeck As Liquid pharmaceutical formulations of 1-[2-(2,4-dimethylsulfanyl)phenyl]piperazine
CA2769872A1 (en) * 2009-08-24 2011-03-03 H. Lundbeck A/S New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine
AU2010313402B2 (en) * 2009-10-30 2015-12-03 Janssen Pharmaceutica Nv 4-substituted-2-phenoxy-phenylamine delta opioid receptor modulators
EP2523945A1 (de) * 2010-01-11 2012-11-21 Theravance, Inc. 1-(2-phenoxymethylphenyl-)piperazinverbindungen als serotonin- und norepinephrin-wiederaufnahmehemmer
EP2550252B1 (de) * 2010-03-22 2015-05-06 Theravance Biopharma R&D IP, LLC 1-(2-phenoxymethylheteroaryl)piperidin und piperazinverbindungen
KR20130060220A (ko) * 2010-04-30 2013-06-07 다케다 야쿠힌 고교 가부시키가이샤 장용성 정제
MA34261B1 (fr) * 2010-04-30 2013-05-02 Takeda Pharmaceutcal Company Ltd Comprime a delitage intestinal
EP2407467A1 (de) 2010-07-14 2012-01-18 Sandoz Ag Kristalline Verbindung von 1-[4-(2-azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol und Milchsäure
TW201212918A (en) 2010-08-23 2012-04-01 Lundbeck & Co As H Therapeutic uses of 1-[2-(2,4-dimethyl-phenylsulfanyl)phenyl]piperazine
PL2720989T3 (pl) 2011-06-20 2017-05-31 H. Lundbeck A/S Deuterowane 1-piperazyno-3-fenyloindany do leczenia schizofrenii
JP6285865B2 (ja) 2011-11-14 2018-02-28 アルファシグマ ソシエタ ペル アチオニ うつ病を有する対象のための処置レジメンを選択するためのアッセイ及び方法
EP2800746B1 (de) * 2012-01-03 2019-04-17 H. Lundbeck A/S Verfahren zur herstellung von 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazin
CA2885266C (en) 2012-09-19 2020-05-12 Sandoz Ag Novel crystalline form of vortioxetine hydrobromide
NZ708595A (en) 2012-12-13 2019-06-28 H Lundbeck As Compositions comprising vortioxetine and donepezil
GEP201706749B (en) * 2013-02-22 2017-10-10 H Lundbeck As Vortioxetine manufacturing process
EP2981520B1 (de) 2013-04-04 2019-03-06 LEK Pharmaceuticals d.d. Neues verfahren zur synthese von 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazin
CN104109135B (zh) * 2013-04-22 2018-10-26 江苏豪森药业集团有限公司 1-[2-(2,4-二甲基苯基硫烷基)-苯基]哌嗪的制备方法
US10414741B2 (en) 2013-09-30 2019-09-17 Cadila Healthcare Limited Amorphous vortioxetine and salts thereof
EP2878596A1 (de) 2013-11-29 2015-06-03 LEK Pharmaceuticals d.d. Synthese von Vortioxetin über (2-(Piperazin-1-yl)phenyl)lithium-Zwischenprodukte
CN104710345B (zh) * 2013-12-17 2017-09-05 江苏恩华药业股份有限公司 用于制备4‑（2‑（4‑甲基苯基硫基））苯基哌啶的化合物、其制备方法及应用
CA2933733A1 (en) 2013-12-20 2015-06-25 Connie Sanchez Morillo Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
EP2894154A1 (de) * 2014-01-14 2015-07-15 LEK Pharmaceuticals d.d. Synthese von Vortioxetin über (2-(piperazin-1-yl)phenyl)anilin-Zwischenprodukte
CN103788019B (zh) * 2014-01-22 2015-10-07 苏州明锐医药科技有限公司 沃替西汀的制备方法
US9822086B2 (en) 2014-01-31 2017-11-21 Egis Gyogyszergyar Zrt. Process for the preparation of vortioxetine salts
EP2930171A1 (de) 2014-04-07 2015-10-14 LEK Pharmaceuticals d.d. Synthese von Vortioxetin über (2,4-Dimethylphenyl) (2-Iodophenyl)sulfan-Zwischenprodukt
CN104059030B (zh) * 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
FR3023320B1 (fr) * 2014-07-03 2017-03-10 Ifp Energies Now Systeme et procede de stockage et de recuperation d'energie par gaz comprime avec stockage de la chaleur au moyen d'un echangeur radial
CZ2014471A3 (cs) * 2014-07-08 2016-01-20 Zentiva, K.S. Způsob přípravy vortioxetinu
US9687484B2 (en) 2014-07-18 2017-06-27 Dipharma Francis S.R.L. Crystalline forms of an antidepressant compound
CN104146953A (zh) * 2014-07-24 2014-11-19 李雪梅 一种氢溴酸沃替西汀注射液
CN104292183B (zh) * 2014-09-29 2016-01-06 杨献美 一种抗抑郁药物沃替西汀的制备方法
WO2016079751A2 (en) 2014-11-17 2016-05-26 Megafine Pharma (P) Ltd. A process for preparation of vortioxetine and polymorphs thereof
EP3023417B1 (de) 2014-11-21 2017-06-28 Dipharma Francis S.r.l. Verfahren zur herstellung von einem antidepressivum und zwischenprodukte davon
CN104447622B (zh) * 2014-11-28 2017-01-04 郑州大明药物科技有限公司 氢溴酸沃替西汀β晶型的制备方法
CN104586756A (zh) * 2015-01-05 2015-05-06 万特制药(海南)有限公司 一种含沃替西汀的口服溶液及其制备方法
CZ201531A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Polymerem stabilizované amorfní formy vortioxetinu
CN104610195B (zh) * 2015-01-30 2017-06-27 上虞京新药业有限公司 沃替西汀的天冬氨酸盐或其水合物及其制备方法和用途
WO2016125191A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Processes for the preparation of vortioxetine hydrobromide
WO2016125190A2 (en) 2015-02-04 2016-08-11 Mylan Laboratories Limited Novel crystalline forms of vortioxetine, premixes, and processes for the preparation thereof
WO2016135636A1 (en) 2015-02-25 2016-09-01 Lupin Limited Process for the preparation of vortioxetine
EP3274330A1 (de) 2015-03-26 2018-01-31 Cipla Limited Verfahren zur herstellung von serotonin-wiederaufnahmehemmern
CN104829557B (zh) * 2015-04-23 2017-06-27 山东百诺医药股份有限公司 一种新化合物1‑[2‑（2,4‑二甲基苯基硫基）苯基]‑2‑氧哌嗪及其制备方法和在沃替西汀合成中的应用
JO3456B1 (ar) 2015-05-13 2020-07-05 H Lundbeck As فيروتيوكسيتين بيروجلوتامات
AU2016296205B2 (en) * 2015-07-17 2021-11-11 Centre Hospitalier Sainte Anne Paris 5-hydroxytryptamine 1B receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
US20180237386A1 (en) * 2015-08-19 2018-08-23 Amneal Pharmaceuticals Company Gmbh Process For Preparation Of Vortioxetine Hydrobromide
WO2017063771A1 (en) * 2015-10-14 2017-04-20 Institut Pasteur 5-hydroxytryptamine 1b receptor-stimulating agent for the treatment of myocardial infarction
CN105461635B (zh) * 2015-11-18 2018-06-08 乳源瑶族自治县大众药品贸易有限公司 苯基哌嗪衍生物及其使用方法和用途
CN105348204B (zh) * 2015-11-18 2018-09-14 乳源瑶族自治县大众药品贸易有限公司 1-杂环基-2-(杂芳基硫基)苯衍生物及其使用方法和用途
US11013830B2 (en) * 2015-11-20 2021-05-25 Institut Pasteur 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
WO2017162536A1 (en) 2016-03-21 2017-09-28 H. Lundbeck A/S Vortioxetine prodrugs
SG11201810644TA (en) 2016-07-01 2018-12-28 H Lundbeck As Vortioxetine dosing regimes for fast onset of antidepressant effect
KR20190038840A (ko) * 2016-07-15 2019-04-09 앵스띠뛰 파스퇴르 피부 및/또는 모발 복구를 위한 5-하이드록시트립타민 1b 수용체-자극제
EP3489225A4 (de) * 2016-07-22 2019-12-18 Jiangsu Nhwaluokang Pharmaceutical Research and Development Co., Ltd. Vortioxetinanalogon und verwendung davon und herstellung davon
US20190224192A1 (en) 2016-08-29 2019-07-25 Cipla Limited Stable Pharmaceutical Composition of Vortioxetine Hydrobromide
CN106349132B (zh) * 2016-08-30 2018-02-02 重庆植恩药业有限公司 沃替西汀中间体杂质及其制备方法和用途
US10519121B2 (en) 2016-12-30 2019-12-31 Apicore Us Llc Process and novel polymorphic form of vortioxetine and its pharmaceutically acceptable salts
CN108409728B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
CN108409729B (zh) * 2017-02-09 2020-11-24 广东东阳光药业有限公司 苯基八氢-1H-吡啶并[1,2-a]吡嗪衍生物及其用途
US10428033B2 (en) 2017-02-15 2019-10-01 Piramal Enterprises Limited Process for the preparation of vortioxetine and salts thereof
WO2018150344A1 (en) 2017-02-17 2018-08-23 Unichem Laboratories Ltd Bioequivalent pharmaceutical composition of vortioxetine hydrobromide
US10836730B2 (en) 2017-02-23 2020-11-17 Unichem Laboratories Ltd. Process for preparation and purification of vortioxetine hydrobromide
JP7121751B2 (ja) * 2017-04-25 2022-08-18 ハー・ルンドベック・アクチエゼルスカベット ボルチオキセチンＨＢｒ α型を製造するための方法
EP3412661A1 (de) 2017-06-08 2018-12-12 Enantia, S.L. Co-kristalle von vortioxetin-hydrobromid und resorcin
KR102026337B1 (ko) 2017-07-07 2019-09-27 영진약품 주식회사 1-[2-(2,4-디메틸페닐설파닐)페닐]피페라진의 신규염 및 이의 제조방법
CN107915685A (zh) * 2017-12-11 2018-04-17 重庆植恩药业有限公司 一种氢溴酸沃替西汀中间体的制备方法
CN108017595A (zh) * 2017-12-20 2018-05-11 安徽源久源科技有限公司 一种1-[2-(2,5-二甲基苯硫基)苯基]哌嗪的制备方法
PL3810582T3 (pl) 2018-06-20 2024-05-13 Vio Ag Pharmaceuticals S.A. Jednonaczyniowy sposób organopseudokatalitycznej aktywacji c-h do wytwarzania wortioksetyny i związku pośredniego wortioksetyny
CN108727393B (zh) * 2018-08-06 2019-10-29 广东东阳光药业有限公司 苯基二氮杂双环衍生物及其用途
CN108863986B (zh) * 2018-08-06 2020-01-21 广东东阳光药业有限公司 二氟甲基取代的苯基哌嗪衍生物及其用途
JP2023520016A (ja) 2020-04-03 2023-05-15 ハー・ルンドベック・アクチエゼルスカベット 感情鈍麻の予防又は処置のための１－［２－（２，４－ジメチルフェニルスルファニル）－フェニル］ピペラジン
GB2622880A (en) 2022-09-30 2024-04-03 Alkaloid Ad Skopje Palatable orodispersible formulation of vortioxetine

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS151755B1 (de) 1971-04-13 1973-11-19
CS151751B1 (de) 1971-04-13 1973-11-19
CS151752B1 (de) 1971-04-13 1973-11-19
CS151753B1 (de) 1971-04-13 1973-11-19
YU163075A (en) * 1975-07-21 1982-05-31 Science Union & Cie Process for preparing new phenoxy derivatives
US4241071A (en) 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
US4198419A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenylthiophenylpiperidines
US4198417A (en) 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
ES2004809A6 (es) 1987-07-29 1989-02-01 Ferrer Int Procedimiento de obtencion de nuevas 1-(2-(fenilmetil)fenil)piperazinas
GB9126311D0 (en) 1991-12-11 1992-02-12 Wellcome Found Substituted diphenylsulfides
ATE294778T1 (de) * 1995-01-23 2005-05-15 Daiichi Suntory Pharma Co Ltd Verbesserung oder heilung von durch ischämischen krankheiten hervorgerufenen symtomen und dafür verwendbare phenylpiperidinverbingungen
CZ293595A3 (cs) 1995-11-09 1999-12-15 Farmak A. S. Deriváty N,N-dimethyl-2-(arylthio)benzylaminu, jejich soli, způsoby jejich přípravy a jejich použití v léčivých přípravcích
FR2757160B1 (fr) * 1996-12-13 1999-03-12 Sanofi Sa 1-phenylalkyl-1,2,3,6-tetrahydropyridines
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
CN1157376C (zh) * 1997-10-31 2004-07-14 第一三得利制药株式会社 芳基哌啶子基丙醇和芳基哌嗪子基丙醇衍生物和含有它们的药物
BR0009421A (pt) 1999-04-02 2002-03-26 Icos Corp Inibidores de ligação lfa-1 aos icams e uso dos mesmos
JP2003528810A (ja) 1999-08-04 2003-09-30 ミレニアム ファーマスーティカルズ インク メラノコルチン−４受容体結合化合物及びその使用方法
US6644364B1 (en) * 1999-09-14 2003-11-11 Pharmacopeia, Inc. Article comprising a multi-channel dispensing head
CZ20022319A3 (cs) * 1999-12-30 2002-10-16 H. Lundbeck A/S Substituovaná fenylpiperazinová sloučenina a farmaceutický prostředek, který ji obsahuje
AU2351701A (en) 1999-12-30 2001-07-16 H. Lundbeck A/S A method for the preparation of substituted benzene derivatives
US6813639B2 (en) 2000-01-26 2004-11-02 Viaclix, Inc. Method for establishing channel-based internet access network
DE10033548C2 (de) 2000-07-11 2002-05-16 Wolfgang Papenbrock Verfahren zur Vorschau von Internetseiten
DE60205727T2 (de) * 2001-01-23 2006-06-29 Eli Lilly And Co., Indianapolis Piperazin- und piperidinderivate als agonisten des melanocortin-rezeptors
WO2002062766A2 (en) 2001-02-07 2002-08-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
CA2467118A1 (en) * 2001-12-20 2003-07-03 H. Lundbeck A/S Aryloxyphenyl and arylsulfanylphenyl derivatives
AR043633A1 (es) 2003-03-20 2005-08-03 Schering Corp Ligandos de receptores de canabinoides
US7732463B2 (en) * 2003-04-04 2010-06-08 H. Lundbeck A/S 4-(2-phenylsulfanyl-phenyl)-piperidine derivatives as serotonin reuptake inhibitors
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
RS52205B2 (sr) * 2006-06-16 2021-05-31 H Lundbeck A/S 1-[2-(2,4-dimetilfenilsulfanil)-fenil]piperazin kao jedinjenje sa kombinovanom aktivnošću ponovnog uzimanja serotonina, 5-ht3 i 5-ht1a, za tretman kognitivnih oštećenja

Also Published As

Publication number Publication date
HU230189B1 (hu) 2015-09-28
AU2006215994A2 (en) 2006-10-05
HUS1400012I1 (hu) 2020-12-28
AR066460A2 (es) 2009-08-19
US20140163043A1 (en) 2014-06-12
AU2006215994A9 (en) 2006-10-05
US20120302553A1 (en) 2012-11-29
CY2014022I1 (el) 2015-12-09
KR100770194B1 (ko) 2007-10-25
US20210276966A1 (en) 2021-09-09
DK1436271T3 (da) 2008-06-09
PT1436271E (pt) 2008-04-10
EP1749818A3 (de) 2008-04-02
US9708280B2 (en) 2017-07-18
PL209253B1 (pl) 2011-08-31
US20060089368A1 (en) 2006-04-27
IS2732B (is) 2011-04-15
HU228956B1 (en) 2013-07-29
BR122012009534B8 (pt) 2019-01-29
NL300652I2 (de) 2016-01-18
NO326443B1 (no) 2008-12-08
HK1072600A1 (en) 2005-09-02
EA200400498A1 (ru) 2004-08-26
PL368442A1 (en) 2005-03-21
EP1749818B1 (de) 2009-09-02
EA007537B1 (ru) 2006-10-27
DK1436271T6 (da) 2022-06-27
CY1110064T1 (el) 2015-01-14
UA93857C2 (uk) 2011-03-25
WO2003029232A1 (en) 2003-04-10
CY2014022I2 (el) 2015-12-09
CN1561336A (zh) 2005-01-05
MXPA04002959A (es) 2004-07-05
BR0212733A (pt) 2004-11-16
KR100783346B1 (ko) 2007-12-07
KR20060118020A (ko) 2006-11-17
JP3955613B2 (ja) 2007-08-08
JP2007031447A (ja) 2007-02-08
NZ531556A (en) 2005-12-23
RS52326B (en) 2012-12-31
MEP6508A (xx) 2010-02-10
EA200601269A1 (ru) 2007-02-27
LTC1436271I2 (lt) 2016-09-12
AU2002333220C1 (en) 2023-10-05
BR122012023120B1 (pt) 2017-03-21
BR122012023120B8 (pt) 2022-01-18
AU2006215994A1 (en) 2006-10-05
US8476279B2 (en) 2013-07-02
CA2462110C (en) 2010-05-11
CA2462110A1 (en) 2003-04-10
RS52865B (en) 2013-12-31
NO20041628L (no) 2004-04-21
US7148238B2 (en) 2006-12-12
HRP20040220A2 (en) 2005-02-28
KR20040047886A (ko) 2004-06-05
EP1436271B1 (de) 2008-02-20
ES2328725T3 (es) 2009-11-17
NL300652I1 (de) 2016-01-18
EP1436271B3 (de) 2022-04-20
NO332355B1 (no) 2012-09-03
AU2002333220A2 (en) 2003-04-14
US20180127389A1 (en) 2018-05-10
BE2014C036I2 (de) 2021-11-22
CA2462110E (en) 2003-04-10
US20110009423A1 (en) 2011-01-13
RS20120158A3 (en) 2013-10-31
JP3896116B2 (ja) 2007-03-22
EG25095A (en) 2011-08-17
US7144884B2 (en) 2006-12-05
US7683053B2 (en) 2010-03-23
SI1436271T1 (sl) 2008-06-30
IL160655A0 (en) 2004-07-25
NO20083446L (no) 2004-04-21
JP3955614B2 (ja) 2007-08-08
BR0212733B1 (pt) 2014-05-13
US9090575B2 (en) 2015-07-28
IS7164A (is) 2004-02-26
US20070060574A1 (en) 2007-03-15
KR20070103515A (ko) 2007-10-23
PT1749818E (pt) 2009-10-06
RS27704A (en) 2006-10-27
DE60233608D1 (de) 2009-10-15
BR122012009534C8 (pt) 2021-05-25
DE60225162T3 (de) 2022-08-11
US20060084662A1 (en) 2006-04-20
JP2007051149A (ja) 2007-03-01
AU2006215994B2 (en) 2008-11-13
DE60225162D1 (de) 2008-04-03
RS20120158A2 (en) 2012-10-31
US20050014740A1 (en) 2005-01-20
EA011096B1 (ru) 2008-12-30
UA81749C2 (uk) 2008-02-11
KR100842702B1 (ko) 2008-07-01
LU92397I2 (fr) 2014-05-12
US8110567B2 (en) 2012-02-07
IS2578B (is) 2010-02-15
ZA200401583B (en) 2005-05-25
CY1107924T1 (el) 2013-09-04
BRPI0212733B8 (pt) 2021-05-25
US10844029B2 (en) 2020-11-24
FR14C0033I1 (de) 2014-06-13
IS8806A (is) 2009-03-10
ES2298425T7 (es) 2022-06-27
NO2014011I2 (no) 2015-08-31
HUP0402313A2 (hu) 2005-02-28
ME00039B (me) 2010-06-10
US20160137620A1 (en) 2016-05-19
ES2298425T3 (es) 2008-05-16
PL210551B1 (pl) 2012-02-29
US7138407B2 (en) 2006-11-21
MY140950A (en) 2010-02-12
FR14C0033I2 (fr) 2014-11-14
BR122012009534B1 (pt) 2018-02-27
CN1319958C (zh) 2007-06-06
EA007537B3 (ru) 2015-02-27
DK1749818T3 (da) 2009-10-12
JP2005505585A (ja) 2005-02-24
ATE386730T1 (de) 2008-03-15
HUP0402313A3 (en) 2010-03-29
AR036659A1 (es) 2004-09-22
NO2014011I1 (no) 2014-05-13
EP1749818A2 (de) 2007-02-07
CO5580746A2 (es) 2005-11-30
AU2002333220B2 (en) 2008-02-07
DE60225162T2 (de) 2009-02-12
EP1436271A1 (de) 2004-07-14

Similar Documents

Publication Publication Date Title
ATE441631T1 (de) Phenylpiperidinderivate als serotonin- wiederaufnahmehemmer
ATE370137T1 (de) 4-(6-gliedriger)-heteroaryl-acyl-pyrrolidin derivate als hcv-inhibitoren
ATE437862T1 (de) Pyrimidin-5-onderivate als ldl-pla2 inhibitoren
ATE452891T1 (de) Pyrimidopyrimidone als kinaseinhibitoren
ATE404564T1 (de) Diazepinoindolderivate als kinaseinhibitoren
DK1515969T3 (da) Spiroindolinpiperidinderivater
DE602004024420D1 (de) Chinazolinderivate als antitumormittel
DE60315862D1 (de) Dihydropyridinonderivate als hne-inhibitoren
ATE256127T1 (de) Betacarbolinderivate als phosphodiesterase- inhibitoren
DE50304983D1 (de) Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
NO20041293D0 (no) Alkyn-aryl-fosfodiesterase-4-inhibitorer
ATE319451T1 (de) Tetrahydrochinolin-derivate
DK1427709T3 (da) 3-substituerede 4-pyrimidonderivater
ATE278690T1 (de) Substituierte pyprolopyridinonderivate als phosphodiesterase-inhibitoren
NO20034970D0 (no) Nye arylheteroalkylaminderivater
DE60203529D1 (de) Indolderivate als cox-ii-inhibitoren
ATE454381T1 (de) Benzofuranderivat
EE200300447A (et) Asendatud bensofuraan-2-karboksamiidide derivaadid
ATE428420T1 (de) Substituierte 8-arylchinoline als phosphodiesterase-4-hemmer
ATE281435T1 (de) Phenyl-heterocyclyl-ether-derivate als serotonin re-uptake inhibitoren
ATE394372T1 (de) G-lactamderivate als prostaglandinagonisten
DE60214138D1 (de) Isoxazolin-derivate als antidepressiva
DE60201463D1 (de) Indanon-Derivate als Duftstoffe
DE60210058D1 (de) Alkoxycarbonylamino-heteroaryl-carbonsäurederivate als ip-antagonisten
NO20035248D0 (no) Nye fenylalkyloksy-fenyl derivater

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1749818

Country of ref document: EP